The ICR responds to the FDA approval of olaparib for women with BRCA-mutant advanced breast cancer 12 Jan 2018
European Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancer 22 Nov 2017
ICR responds to NICE approval of new breakthrough drugs on the NHS for women with advanced breast cancer 16 Nov 2017
Breakthrough for advanced head and neck cancer patients as nivolumab made available on the Cancer Drugs Fund 13 Oct 2017
ICR reacts to decision to make the immunotherapy nivolumab available on the Cancer Drugs Fund for non-small cell lung cancers 20 Sep 2017